Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey

D. Navarro, R. San-Juan, O. Manuel, E. Gimenez, M. Fernandez-Ruiz, H. H. Hirsch, P. A. Grossi, J. M. Aguado, on behalf of the European Study Group of Infections in Compromised Hosts (ESGICH) from the Society of Clinical Microbiology ESGICH CMV Survey Study Group, Infectious Diseases (ESCMID)

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

BACKGROUND: Scant information is available about how transplant centers are managing their use of quantitative molecular testing (QNAT) assays for active cytomegalovirus (CMV) infection monitoring in solid organ transplant (SOT) recipients. The current study was aimed at gathering information on current practices in the management of CMV infection across European centers in the era of molecular testing assays. METHODS: A questionnaire-based cross-sectional survey study was conducted by the European Study Group of Infections in Immunocompromised Hosts (ESGICH) of the Society of Clinical Microbiology and Infectious Diseases (ESCMID). The invitation and a weekly reminder with a personal link to an Internet service provider (https://es.surveymonkey.com/) was sent to transplant physicians, transplant infectious diseases specialists, and clinical virologists working at 340 European transplant centers. RESULTS: Of the 1181 specialists surveyed, a total of 173 responded (14.8%): 73 transplant physicians, 57 transplant infectious diseases specialists, and 43 virologists from 173 institutions located at 23 different countries. The majority of centers used QNAT assays for active CMV infection monitoring. Most centers preferred commercially available real-time polymerase chain reaction (RT-PCR) assays over laboratory-developed procedures for quantifying CMV DNA load in whole blood or plasma. Use of a wide variety of DNA extraction platforms and RT-PCR assays was reported. All programs used antiviral prophylaxis, preemptive therapy, or both, according to current guidelines. However, the centers used different criteria for starting preemptive antiviral treatment, for monitoring systemic CMV DNA load, and for requesting genotypic assays to detect emerging CMV-resistant variants. CONCLUSIONS: Significant variation in CMV infection management in SOT recipients still remains across European centers in the era of molecular testing. International multicenter studies are required to achieve commutability of CMV testing and antiviral management procedures.
Original languageEnglish
Pages (from-to)10.1111/tid.12773. Epub 2017 Oct 25
JournalTransplant Infectious Disease
Volume19
Issue number6
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Molecular Pathology
Cytomegalovirus Infections
Immunocompromised Host
Transplants
Infection
Cytomegalovirus
Antiviral Agents
Communicable Diseases
Real-Time Polymerase Chain Reaction
DNA
Cross-Sectional Studies
Physicians
Transplant Recipients
Surveys and Questionnaires
Practice Management
Microbiology
Internet
Multicenter Studies
Guidelines
Therapeutics

Keywords

  • cytomegalovirus
  • solid organ transplantation
  • survey

Cite this

Navarro, D., San-Juan, R., Manuel, O., Gimenez, E., Fernandez-Ruiz, M., Hirsch, H. H., ... (ESCMID), I. D. (2017). Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey. Transplant Infectious Disease, 19(6), 10.1111/tid.12773. Epub 2017 Oct 25. https://doi.org/10.1111/tid.12773 [doi]

Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey. / Navarro, D.; San-Juan, R.; Manuel, O.; Gimenez, E.; Fernandez-Ruiz, M.; Hirsch, H. H.; Grossi, P. A.; Aguado, J. M.; ESGICH CMV Survey Study Group, on behalf of the European Study Group of Infections in Compromised Hosts (ESGICH) from the Society of Clinical Microbiology; (ESCMID), Infectious Diseases.

In: Transplant Infectious Disease, Vol. 19, No. 6, 01.12.2017, p. 10.1111/tid.12773. Epub 2017 Oct 25.

Research output: Contribution to journalArticle

Navarro, D, San-Juan, R, Manuel, O, Gimenez, E, Fernandez-Ruiz, M, Hirsch, HH, Grossi, PA, Aguado, JM, ESGICH CMV Survey Study Group, OBOTESGOIICHESGICHFTSOCM & (ESCMID), ID 2017, 'Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey', Transplant Infectious Disease, vol. 19, no. 6, pp. 10.1111/tid.12773. Epub 2017 Oct 25. https://doi.org/10.1111/tid.12773 [doi]
Navarro, D. ; San-Juan, R. ; Manuel, O. ; Gimenez, E. ; Fernandez-Ruiz, M. ; Hirsch, H. H. ; Grossi, P. A. ; Aguado, J. M. ; ESGICH CMV Survey Study Group, on behalf of the European Study Group of Infections in Compromised Hosts (ESGICH) from the Society of Clinical Microbiology ; (ESCMID), Infectious Diseases. / Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey. In: Transplant Infectious Disease. 2017 ; Vol. 19, No. 6. pp. 10.1111/tid.12773. Epub 2017 Oct 25.
@article{599ea798db9c45929b26d89ca40819c5,
title = "Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey",
abstract = "BACKGROUND: Scant information is available about how transplant centers are managing their use of quantitative molecular testing (QNAT) assays for active cytomegalovirus (CMV) infection monitoring in solid organ transplant (SOT) recipients. The current study was aimed at gathering information on current practices in the management of CMV infection across European centers in the era of molecular testing assays. METHODS: A questionnaire-based cross-sectional survey study was conducted by the European Study Group of Infections in Immunocompromised Hosts (ESGICH) of the Society of Clinical Microbiology and Infectious Diseases (ESCMID). The invitation and a weekly reminder with a personal link to an Internet service provider (https://es.surveymonkey.com/) was sent to transplant physicians, transplant infectious diseases specialists, and clinical virologists working at 340 European transplant centers. RESULTS: Of the 1181 specialists surveyed, a total of 173 responded (14.8{\%}): 73 transplant physicians, 57 transplant infectious diseases specialists, and 43 virologists from 173 institutions located at 23 different countries. The majority of centers used QNAT assays for active CMV infection monitoring. Most centers preferred commercially available real-time polymerase chain reaction (RT-PCR) assays over laboratory-developed procedures for quantifying CMV DNA load in whole blood or plasma. Use of a wide variety of DNA extraction platforms and RT-PCR assays was reported. All programs used antiviral prophylaxis, preemptive therapy, or both, according to current guidelines. However, the centers used different criteria for starting preemptive antiviral treatment, for monitoring systemic CMV DNA load, and for requesting genotypic assays to detect emerging CMV-resistant variants. CONCLUSIONS: Significant variation in CMV infection management in SOT recipients still remains across European centers in the era of molecular testing. International multicenter studies are required to achieve commutability of CMV testing and antiviral management procedures.",
keywords = "cytomegalovirus, solid organ transplantation, survey",
author = "D. Navarro and R. San-Juan and O. Manuel and E. Gimenez and M. Fernandez-Ruiz and Hirsch, {H. H.} and Grossi, {P. A.} and Aguado, {J. M.} and {ESGICH CMV Survey Study Group}, {on behalf of the European Study Group of Infections in Compromised Hosts (ESGICH) from the Society of Clinical Microbiology} and (ESCMID), {Infectious Diseases}",
note = "LR: 20171227; CI: (c) 2017; JID: 100883688; OTO: NOTNLM; 2017/05/03 00:00 [received]; 2017/05/17 00:00 [revised]; 2017/06/11 00:00 [accepted]; 2017/09/01 06:00 [pubmed]; 2017/09/01 06:00 [medline]; 2017/09/01 06:00 [entrez]; ppublish",
year = "2017",
month = "12",
day = "1",
doi = "10.1111/tid.12773 [doi]",
language = "English",
volume = "19",
pages = "10.1111/tid.12773. Epub 2017 Oct 25",
journal = "Transplant Infectious Disease",
issn = "1398-2273",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey

AU - Navarro, D.

AU - San-Juan, R.

AU - Manuel, O.

AU - Gimenez, E.

AU - Fernandez-Ruiz, M.

AU - Hirsch, H. H.

AU - Grossi, P. A.

AU - Aguado, J. M.

AU - ESGICH CMV Survey Study Group, on behalf of the European Study Group of Infections in Compromised Hosts (ESGICH) from the Society of Clinical Microbiology

AU - (ESCMID), Infectious Diseases

N1 - LR: 20171227; CI: (c) 2017; JID: 100883688; OTO: NOTNLM; 2017/05/03 00:00 [received]; 2017/05/17 00:00 [revised]; 2017/06/11 00:00 [accepted]; 2017/09/01 06:00 [pubmed]; 2017/09/01 06:00 [medline]; 2017/09/01 06:00 [entrez]; ppublish

PY - 2017/12/1

Y1 - 2017/12/1

N2 - BACKGROUND: Scant information is available about how transplant centers are managing their use of quantitative molecular testing (QNAT) assays for active cytomegalovirus (CMV) infection monitoring in solid organ transplant (SOT) recipients. The current study was aimed at gathering information on current practices in the management of CMV infection across European centers in the era of molecular testing assays. METHODS: A questionnaire-based cross-sectional survey study was conducted by the European Study Group of Infections in Immunocompromised Hosts (ESGICH) of the Society of Clinical Microbiology and Infectious Diseases (ESCMID). The invitation and a weekly reminder with a personal link to an Internet service provider (https://es.surveymonkey.com/) was sent to transplant physicians, transplant infectious diseases specialists, and clinical virologists working at 340 European transplant centers. RESULTS: Of the 1181 specialists surveyed, a total of 173 responded (14.8%): 73 transplant physicians, 57 transplant infectious diseases specialists, and 43 virologists from 173 institutions located at 23 different countries. The majority of centers used QNAT assays for active CMV infection monitoring. Most centers preferred commercially available real-time polymerase chain reaction (RT-PCR) assays over laboratory-developed procedures for quantifying CMV DNA load in whole blood or plasma. Use of a wide variety of DNA extraction platforms and RT-PCR assays was reported. All programs used antiviral prophylaxis, preemptive therapy, or both, according to current guidelines. However, the centers used different criteria for starting preemptive antiviral treatment, for monitoring systemic CMV DNA load, and for requesting genotypic assays to detect emerging CMV-resistant variants. CONCLUSIONS: Significant variation in CMV infection management in SOT recipients still remains across European centers in the era of molecular testing. International multicenter studies are required to achieve commutability of CMV testing and antiviral management procedures.

AB - BACKGROUND: Scant information is available about how transplant centers are managing their use of quantitative molecular testing (QNAT) assays for active cytomegalovirus (CMV) infection monitoring in solid organ transplant (SOT) recipients. The current study was aimed at gathering information on current practices in the management of CMV infection across European centers in the era of molecular testing assays. METHODS: A questionnaire-based cross-sectional survey study was conducted by the European Study Group of Infections in Immunocompromised Hosts (ESGICH) of the Society of Clinical Microbiology and Infectious Diseases (ESCMID). The invitation and a weekly reminder with a personal link to an Internet service provider (https://es.surveymonkey.com/) was sent to transplant physicians, transplant infectious diseases specialists, and clinical virologists working at 340 European transplant centers. RESULTS: Of the 1181 specialists surveyed, a total of 173 responded (14.8%): 73 transplant physicians, 57 transplant infectious diseases specialists, and 43 virologists from 173 institutions located at 23 different countries. The majority of centers used QNAT assays for active CMV infection monitoring. Most centers preferred commercially available real-time polymerase chain reaction (RT-PCR) assays over laboratory-developed procedures for quantifying CMV DNA load in whole blood or plasma. Use of a wide variety of DNA extraction platforms and RT-PCR assays was reported. All programs used antiviral prophylaxis, preemptive therapy, or both, according to current guidelines. However, the centers used different criteria for starting preemptive antiviral treatment, for monitoring systemic CMV DNA load, and for requesting genotypic assays to detect emerging CMV-resistant variants. CONCLUSIONS: Significant variation in CMV infection management in SOT recipients still remains across European centers in the era of molecular testing. International multicenter studies are required to achieve commutability of CMV testing and antiviral management procedures.

KW - cytomegalovirus

KW - solid organ transplantation

KW - survey

U2 - 10.1111/tid.12773 [doi]

DO - 10.1111/tid.12773 [doi]

M3 - Article

VL - 19

SP - 10.1111/tid.12773. Epub 2017 Oct 25

JO - Transplant Infectious Disease

JF - Transplant Infectious Disease

SN - 1398-2273

IS - 6

ER -